Drug guidance
Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
Condition
Breast
Cancer
12 July 2022
Published on 12 Jul 2022
Last Updated on 12 Jul 2022
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Olaparib 100 mg and 150 mg tablets for treating germline BRCA-mutated, human epidermal growth factor receptor (HER2) negative, locally advanced or metastatic breast cancer in patients who have been previously treated with chemotherapy.
Subsidy status
Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.
MAF assistance does not apply to olaparib 50 mg capsules or any formulations or strengths of talazoparib for treating BRCA-mutated, HER2-negative advanced breast cancer.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.